Simulations Plus Reports Third Quarter Fiscal 2021 Financial Results
Third quarter total revenue increased 4% to $12.8 million, with software revenue up 21%;
Board of Directors announces quarterly dividend of $0.06 per share
LANCASTER, Calif. (BUSINESS WIRE) Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today reported financial results for its third quarter of fiscal 2021, ended May 31, 2021.
Third Quarter Fiscal 2021 Financial highlights (compared with the corresponding period last fiscal year):
Total revenue increased 4% to $12.8 million;
Software revenue increased 21% to $8.3 million;
Services revenue declined 18% to $4.5 million;
Gross profit increased 7% to $10.3 million;
Press release content from Business Wire. The AP news staff was not involved in its creation.
Simulations Plus Enters Agreement with Distributor in China
February 2, 2021 GMT
LANCASTER, Calif. (BUSINESS WIRE) Feb 2, 2021
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has entered into a distribution agreement with Mosim, one of China’s leading biopharmaceutical services companies, to distribute MonolixSuite™, the Lixoft division’s pharmacokinetic/pharmacodynamic (PK/PD) modeling platform, in China.
ADVERTISEMENT
Founded in 2015, Mosim was the first clinical contract research organization (CRO) providing clinical pharmacology services in China. During the last 5 years, by expanding its clinical operation team with a focus on clinical pharmacology studies, Mosim has become a full service clinical CRO. With a staff of over 100
Press release content from Business Wire. The AP news staff was not involved in its creation.
Simulations Plus Awards Infrastructure Improvement Grant to Makerere University Department of Pharmacology and Therapeutics
January 14, 2021 GMT
LANCASTER, Calif. (BUSINESS WIRE) Jan 14, 2021
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of population pharmacokinetic and pharmacodynamic modeling and simulation services, today announced that its Cognigen division has awarded a grant to the Department of Pharmacology and Therapeutics at Makerere University in Kampala, Uganda, the country’s largest and oldest institution of higher learning, to fund upgraded internet capabilities, ensuring access to Cognigen’s KIWI TM platform. Access to this web-based knowledge-sharing platform will accelerate the University’s pharmaceutical research efforts and quantitative approaches, including modeling and simulation.
First quarter revenue of $10.7 million, reflecting 14% year-over-year growthBoard of Directors announces quarterly dividend of $0.06 per shareLANCASTER, Calif. (BUSINESS WIRE) Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemic.
News Category Global Banking & Finance Reviews
Simulations Plus Enters New Funded Collaboration to Enhance Top-Rated GastroPlus® ACAT™ Model for Oral Absorption of Peptides
Simulations Plus Enters New Funded Collaboration to Enhance Top-Rated GastroPlus® ACAT™ Model for Oral Absorption of Peptides Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has entered into a new funded collaboration with a large pharmaceutical company to add novel mechanisms for oral peptide formulations within the top-rated GastroPlus Advanced Compartmental Absorption and Transit (ACAT„¢) mechanistic model. Our partner, a frequent user of the GastroPlus platform across multiple research sites worldwide, has a growing portion of their development pipeline focused on therapeutic peptides and proteins, said Dr. Viera Lukacova, chief scientist at Simul